You are here: Industry Insights > Bristol Myers Squibb

News List

BMS’ deucravacitinib tops Otezla in two psoriasis studies pharmatimes
April 27, 2021
Bristol Myers Squibb’s investigational selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib topped Amgen’s Otezla in two Phase III psoriasis studies.
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® for Adults with Acute Myeloid Leukemia in First Remission americanpharmaceuticalreview
April 26, 2021
Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Onureg® (azacitidine tablets; CC-486) as a maintenance therapy in adult patients with ...
Bristol Myers Squibb Expands at Cambridge Crossing contractpharma
April 19, 2021
DivcoWest announced that 250 Water Street at Cambridge Crossing (CX), the new 43-acre neighborhood under construction at the intersection of Cambridge, Somerville, and Boston, is now fully-leased following an expansion of Bristol Myers Squibb’s ...
Japan approves Bristol Myers Squibb’s B-cell lymphoma therapy pharmaceutical-business-review
March 31, 2021
Bristol Myers Squibb has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Breyanzi (lisocabtagene maraleucel; liso-cel) to treat patients suffering from relapsed or refractory (R/R) large B-cell lymphoma (LBCL) and R/R ...
Bristol Myers Squibb and bluebird bio get US FDA nod for Abecma (idecabtagene vicleucel) to treat relapsed or refractory multiple myeloma expresspharma
March 29, 2021
Abecma is a first-in-class BCMA-directed personalised immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma.
Compugen Expands Collaboration with Bristol Myers Squibb in COM701, Opdivo Study americanpharmaceuticalreview
February 26, 2021
Compugen announced the expansion of its clinical collaboration agreement with Bristol Myers Squibb. Under the amended agreement, Bristol Myers Squibb will supply Opdivo® (nivolumab), its PD-1 inhibitor, for Compugen's Phase 1b cohort expansion study ...
Molecular Templates Establishes Multi-Target Collaboration with Bristol Myers Squibb americanpharmaceuticalreview
February 24, 2021
Molecular Templates has entered into a worldwide strategic research collaboration with Bristol Myers Squibb to discover and develop multiple novel therapies designed for specific oncology targets.
FDA Approves BMS CAR-T Cell Therapy contractpharma
February 10, 2021
Breyanzi is a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of relapsed or refractory large B-cell lymphoma.
WuXi STA to buy Swiss pharma manufacturing facility from Bristol Myers Squibb pharmaceutical-business-review
February 07, 2021
WuXi STA, a subsidiary of Chinese pharmaceutical company WuXi AppTec, has agreed to buy the Couvet, Switzerland-based manufacturing facility from Bristol Myers Squibb.
CDMO WuXi STA Expands Footprint in Europe contractpharma
February 03, 2021
WuXi STA, a subsidiary of WuXi AppTec, has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland.

Previous page 1 2 3 4 Next page